| 000 | 01423 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250518001123.0 | ||
| 264 | 0 | _c20190827 | |
| 008 | 201908s 0 0 eng d | ||
| 022 | _a1526-632X | ||
| 024 | 7 |
_a10.1212/WNL.0000000000006396 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMoreno, Gabriel M | |
| 245 | 0 | 0 |
_aMortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine. _h[electronic resource] |
| 260 |
_bNeurology _c10 2018 |
||
| 300 |
_a797-799 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntipsychotic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aParkinson Disease _xcomplications |
| 650 | 0 | 4 |
_aPiperidines _xtherapeutic use |
| 650 | 0 | 4 |
_aPsychotic Disorders _xdrug therapy |
| 650 | 0 | 4 |
_aQuetiapine Fumarate _xtherapeutic use |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aUrea _xanalogs & derivatives |
| 700 | 1 | _aGandhi, Rhea | |
| 700 | 1 | _aLessig, Stephanie L | |
| 700 | 1 | _aWright, Brenton | |
| 700 | 1 | _aLitvan, Irene | |
| 700 | 1 | _aNahab, Fatta B | |
| 773 | 0 |
_tNeurology _gvol. 91 _gno. 17 _gp. 797-799 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1212/WNL.0000000000006396 _zAvailable from publisher's website |
| 999 |
_c28877177 _d28877177 |
||